GOVX vs. ESLA, BDRX, SNYR, MAAQ, RANI, MRNS, ALLK, INKT, ENLV, and NRSN
Should you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Estrella Immunopharma (ESLA), Biodexa Pharmaceuticals (BDRX), Synergy CHC (SNYR), Mana Capital Acquisition (MAAQ), Rani Therapeutics (RANI), Marinus Pharmaceuticals (MRNS), Allakos (ALLK), MiNK Therapeutics (INKT), Enlivex Therapeutics (ENLV), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry.
GeoVax Labs vs. Its Competitors
GeoVax Labs (NASDAQ:GOVX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.
In the previous week, GeoVax Labs had 6 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for GeoVax Labs and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.89 beat GeoVax Labs' score of 0.85 indicating that Estrella Immunopharma is being referred to more favorably in the news media.
GeoVax Labs currently has a consensus target price of $8.88, indicating a potential upside of 1,186.05%. Estrella Immunopharma has a consensus target price of $16.00, indicating a potential upside of 1,813.88%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than GeoVax Labs.
Estrella Immunopharma has lower revenue, but higher earnings than GeoVax Labs. Estrella Immunopharma is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.
6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are owned by institutional investors. 5.7% of GeoVax Labs shares are owned by insiders. Comparatively, 55.1% of Estrella Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Estrella Immunopharma has a net margin of 0.00% compared to GeoVax Labs' net margin of -438.20%. GeoVax Labs' return on equity of -511.96% beat Estrella Immunopharma's return on equity.
GeoVax Labs has a beta of 3.36, indicating that its stock price is 236% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.
Summary
GeoVax Labs beats Estrella Immunopharma on 9 of the 16 factors compared between the two stocks.
Get GeoVax Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GeoVax Labs Competitors List
Related Companies and Tools
This page (NASDAQ:GOVX) was last updated on 7/16/2025 by MarketBeat.com Staff
Free GOVX Stock Alerts